Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Which scan is better for spotting brain tumors? tiny study aims to find out

NCT ID NCT04298541

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled This study
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Sep 01, 2026 · Updated 3 times

Summary

This study will compare two types of PET scans (using different radioactive tracers) in 6 adults with suspected meningioma who are scheduled for surgery. Each person will get both scans at least 24 hours apart. The goal is to see which tracer gives clearer images of the tumor, which could help doctors better diagnose and plan treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Ga-68-DOTATATE and Ga-68-DOTATOC (radioactive tracers for PET scans)
What this could lead to
If successful, this could help determine which tracer is better for detecting meningioma, potentially improving diagnosis and treatment planning.
What could go wrong
This is a very small, early-phase study with only 6 participants, so results may not apply to everyone. It focuses on imaging comparison, not treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

Aug 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 89 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult patients with clinically suspected meningioma * Patients planned for surgery - undergoing preoperative workup * No contraindications to either radiotracer Exclusion Criteria: * Age less than 18 years * Inability to lay on the scanner table for the required period of time, e.g., due to bone pain or claustrophobia.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Meningioma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Weill Cornell Medical College of Cornell University

    New York, New York, 10021, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.